Bioventix plc
(“Bioventix” or the “Company”)
Posting of Annual
Report and Notice of AGM
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, confirms that
its Annual Report and Accounts for the year ended 30 June 2021 and the Notice of Annual General
Meeting (“AGM”) has been posted to shareholders.
These documents are available on the Company's website at
www.bioventix.com.
The AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG
at 2.00 p.m. on 9 December 2021.
The Board continues to monitor the situation surrounding
COVID-19 and the advice from the Government on public gatherings.
If the Government’s guidance changes at any point prior to the AGM,
such that shareholders are unable to attend in person, the Company
will update shareholders through an announcement to the London
Stock Exchange and on the Company’s website. In light of this
uncertainty, the Board strongly encourages shareholders to submit a
proxy vote in advance of the AGM and to appoint the Chairman of the
AGM as their proxy, rather than a named person who, if
circumstances change, may not the able to attend the AGM.
For further information please
contact:
Bioventix
plc
Peter Harrison
Bruce Hiscock |
Chief Executive Officer
Chief Financial Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.
